Healthcare

Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company focused on breast aesthetics and reconstruction, reported Q3 2026 total revenue of $72.0 million, representing 33.9% growth over the $53.8 million reported in Q3 2025. U.S. revenue was the primary growth driver, surging 119.0% …

Fortrea Holdings (NASDAQ:FTRE), a leading global contract research organization, reported third quarter 2026 revenues of $691.5 million. The company maintained a book-to-bill ratio of 1.12x for both the quarter and trailing 12 months, indicating that newBusinessbookings continued to outpace revenue recognition—a positive signal for …

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, reported activities for the first quarter of FY2027, ending September 30, 2026. The quarter was defined by significant strategic decisions stemming from the earlier discontinuation of TACTI-004, the company's …

Incyte Corporation (NASDAQ:INCY) reported Q3 2026 total revenue of $1.56 billion, an increase of 14% compared to the third quarter of 2025. Total net product sales were $1.32 billion, also up 14% year over year, as growth across Opzelura and the Hematology and Oncology …

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), the Richmond, Virginia-based biopharmaceutical company focused on opioid use disorder treatment, reported its highest-ever quarterly net income and adjusted EBITDA in the third quarter of 2026. Net income reached $137 million, or $1.12 per diluted share, compared with $42 million, …

Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company, reported total revenues of $524.4 million for the third quarter of 2026, a period defined by accelerating commercial momentum behind BRINSUPRI — its treatment for non-cystic fibrosis bronchiectasis — and continued growth from the established ARIKAYCE franchise. …

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), the company behind the FDA-approved TIL therapy lifileucel, presented updated efficacy data from its IOV-LUN-202 Phase 2 trial along with a refined precision development strategy for non-squamous metastatic non-small-cell lung cancer at a medical conference in October 2026. The data, …